Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab-Paclitaxel

The document reports on three cases of hemodialysis patients with unresectable advanced or recurrent gastric cancer (URGC) who were treated with chemotherapy regimens involving paclitaxel and nab-paclitaxel. The first two cases, a 71-year-old man and a 64-year-old man, received paclitaxel on days 1, 8, and 15 of a 28-day cycle, experiencing adverse reactions such as Grade 2 anorexia, nausea, hair loss, and Grade 3 neutropenia and anemia, but no severe Grade 4 adverse events. Their liver metastases showed a partial response for over six months. The third case, a 62-year-old man, initially had a Grade 3 drug eruption from paclitaxel, likely due to the solvent used. He was switched to nab-paclitaxel, which did not cause a recurrence of the drug eruption. The conclusion drawn from these cases is that paclitaxel and nab-paclitaxel can be safe and effective for URGC patients on hemodialysis.